

**21 February 2022**

**Section 708A(5) Cleansing Notice Exercise of Options**

**HeraMED Limited** (ASX:HMD) ("**HeraMED**" or the "**Company**"), advises that the Company issued 111,109 Shares on 21 February 2022 on the exercise of 111,109 unlisted options exercisable at \$0.20 on or before 15 June 2022 (HMDAR).

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act ("the Act"):

1. the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of chapter 2M of the Act as they apply to the Company and section 674 of the Act; and
3. as at the date of this notice, there is no information that is 'excluded information' under section 708A(7) and (8) of the Act.

This announcement has been authorised by the Board of HeraMED Limited.

**-ENDS-**

**HeraMED Limited**

CEO and Co-Founder

David Groberman

M: +972 52 6991188

E: David@hera-med.com

**Company Secretary**

Jonathan Hart

T: +61 2 7251 1888

E: Jonathan@hera-med.com

**Investor Enquiries**

PAC Partners

Tim Chapman

T: 61 419 897 062

E: tchapman@pacpartners.com.au

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data, and a digital social networking dashboard.